Posted by Michael Wonder on 08 Apr 2026
Apotex strengthens osteoporosis care in Canada with Health Canada's approval of Denoza, a denosumab biosimilar
7 April 2026 - Apotex today announced that Health Canada has approved Denoza (denosumab injection), a biosimilar to Prolia, for its authorised indications.
These include the treatment of post-menopausal women with osteoporosis at high risk for fracture and the treatment of osteoporosis in men at high risk for fracture.
